Prothena | PRTA - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amgen USD 4.61B 777M 2026-06
Biogen USD 419.5M 663.3M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Exelixis USD 268.42M 20.01M 2026-09
Immunic USD -23.33M 2.67M 2025-12
Incyte USD -707.47M 1.41B 2026-09
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
MacroGenics USD -13.85M 19.59M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Prothena USD -18.69M 44.48M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.26B 11.3M 2026-09